A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
Corinne Maurice‐Dror, Ronan Le Moigne, Ulka N. Vaishampayan, Bruce Montgomery, Michael S. Gordon, Nan Hyung Hong, Leah DiMascio, Frank Perabo, Kim N.
Topics & Concepts
TolerabilityMedicineProstate cancerNauseaPharmacokineticsAdverse effectInternal medicineVomitingAndrogen receptorPharmacologyOncologyCancerGastroenterologyProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments